Here: succinct highlights from new studies may offer you insights about multiple sclerosis you didn't have before.
MS and cigarettes; statins and secondary progressive MS; transitioning from Tysabri in JC+ recipients; cerebrospinal venous insufficiency and MS; and marijuana for MS symptoms. . . Here: key points from 5 new studies that you might have missed.
The evidence against cigarette smoking continues to mount. It is well established that smoking increases the risk of multiple sclerosis--although this is not the same as saying that smoking causes MS. We still don’t know conclusively how smoking can influence MS risk and progression. A clearer understanding can help us further understand MS pathogenesis. Click here for more information.Click here for original article
A trial, recently published in The Lancet, showed that high-dose simvastatin reduced the annualized rate of whole-brain atrophy compared with placebo, and was well tolerated and safe in patients with secondary progressive MS. Click here for more information.
Because of its remarkable effectiveness, Tysabri is back on the market and widely used under particular conditions. So, how do we use Tysabri responsibly? Click here for more information.
Chronic cerebrospinal venous insufficiency (CCSVI) is not more prevalent in patients with multiple sclerosis, as was reported in 2009. CCSVI is neither specific or causative for MS.Click here for more information.
A review by the American Academy of Neurology found that medical marijuana only in pill or oral spray form can help treat some symptoms of multiple sclerosis. Click Here
